Key facts
- ProSeek Bio’s last known valuation is $3.9M (Mar 2026).
- It has raised $1.1M; the latest was Seed Round ($1.1M) in Mar 2026.
- Notable investors include CSIRO ON Accelerate, Edale Capital, AngelLoop, AusHealth, Medtech Global — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for ProSeek Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for ProSeek Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProSeek Bio
Developer of biomarker-based in vitro diagnostics intended to improve detection of ovarian cancer and other women's health conditions. The company offers a proprietary glycoproteomics mass spectrometry platform for discovering, validating, and measuring multiple glycoform markers without antibodies, enabling healthcare providers to make earlier and more accurate diagnoses of diseases.
- Sector
- Healthcare
- HQ
- Brisbane, Australia
- Founded
- 2023
- Employees
- 10
- Website
- proseek.bio/
- Ownership
- Privately Held (backing)
ProSeek Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProSeek Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProSeek Bio in its N-PORT filings yet. We sweep new filings monthly.